Combination 2

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Non-Small Cell Lung CarcinomaCarcinoma, Renal CellSolid Tumor Cancer

45 competitors in Non-Small Cell Lung Carcinoma

#DrugCompanyPhaseTrials

1

Tabrecta

Novartis

Approved

12

Retevmo

Eli Lilly

Approved

—3

Rozlytrek

Roche

Approved

—4

Lumakras

Amgen

Approved

—5

Keytruda

Merck & Co.

Phase 3

66

Tepmetko

EMD Serono

Approved

—7

Krazati

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

—8

Tagrisso

AstraZeneca

Phase 3

29

Imjudo

AstraZeneca

Phase 3

110

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

4Show 33 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Aztreonam1 trial

To Investigate the Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI)

Completed·Pfizer·Phase 1·NCT01689207·222 enrolled

Breast Cancer1 trial

Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer

Not yet recruiting·PPeking University Cancer Hospital & Institute··NCT07470203·42 enrolled

Renal Cell Carcinoma1 trial

A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma

Terminated·Pfizer·Phase 1/2·NCT00417677·124 enrolled

HCV1 trial

Neurocognitive Performance and Emotional State in HCV Patients With IFN-free Antiviral Therapy

Unknown status·UUniversity of Wuerzburg·N/A·NCT02469012·30 enrolled

Solid Tumor Cancer1 trial

A Phase 1/2, First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors

Recruiting·AAvenzo Therapeutics, Inc.·Preclinical·NCT07038343·480 enrolled

3 more indications

Non-Small Cell Lung Carcinoma1 trial

AN INTERVENTIONAL OPEN-LABEL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF PF-08634404 IN COMBINATION WITH DIFFERENT ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

Recruiting·Pfizer·Preclinical·NCT07227298·162 enrolled

Carcinoma, Renal Cell1 trial

AN INTERVENTIONAL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA

Recruiting·Pfizer·Preclinical·NCT07227415·224 enrolled

HER2-positive Breast Cancer1 trial

A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)

Active, not recruiting·Pfizer·Phase 3·NCT05132582·654 enrolled

Details

Drug Info

Related News